SCHEMBL17087344

SCHEMBL17087344

CCn1c(CN(C)Cc2ccc(C(=O)NO)cc2)nc2c(N3CCOCC3)nc(-c3ccc(OC)nc3)nc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 20/20 0.79
▸ PIK3R1 P27986 5/20 0.66
▸ HDAC2 Q92769 4/20 0.66
▸ HDAC10 Q969S8 4/20 0.66
▸ HDAC11 Q96DB2 4/20 0.66
▸ HDAC6 Q9UBN7 4/20 0.66
▸ PIK3CD O00329 3/20 0.66
▸ HDAC3 O15379 3/20 0.66
▸ HDAC4 P56524 3/20 0.66
▸ HDAC7 Q8WUI4 3/20 0.66
▸ HDAC8 Q9BY41 3/20 0.66
▸ HDAC9 Q9UKV0 3/20 0.66
▸ HDAC5 Q9UQL6 3/20 0.66
▸ NCOR2 Q9Y618 3/20 0.66
▸ PIK3CG P48736 2/20 0.66
▸ PIK3CA P42336 5/20 0.61
▸ PIK3CB P42338 2/20 0.56
▸ MTOR P42345 1/20 0.53
▸ PRKDC P78527 1/20 0.53
▸ KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18505769 0.94 HDAC1 (0.70) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL17087417 0.90 HDAC1 (0.68) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18490829 0.90 HDAC1 (0.68) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL17078384 0.88 HDAC1 (0.76) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18181539 0.88 HDAC1 (1.00) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18505797 0.88 HDAC1 (0.65) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18505772 0.88 HDAC1 (0.65) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL17078413 0.83 HDAC1 (0.65) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18505783 0.83 HDAC1 (0.67) HDAC1PIK3R1HDAC2HDAC10HDAC11
SCHEMBL18518254 0.80 HDAC1 (0.57) HDAC1PIK3R1HDAC2HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265512-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-09-20 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-9957270-B2 Fused pyrimidine-based hydroxamate derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-05-01 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-02-16 — — US disclosed
WO-2015137887-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044162-A1 Fused Pyrimidine-Based Hydroxamate Derivatives HDAC1, HDAC2, HDAC5 HDAC1 1/4885PIK3R1 934/4885HDAC2 2/4885
US-20180265512-A1 FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES HDAC1, HDAC5, HDAC2 HDAC1 1/4885PIK3R1 1108/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback